What does the Japanese patent application for Oryzon Genomics’ vafidemstat cover?

The allowed claims cover the use of vafidemstat to treat aggression and social withdrawal, which Oryzon Genomics describes as symptoms associated with several central nervous system disorders.

Has Oryzon Genomics already received a granted Japanese patent for vafidemstat?

No; Oryzon Genomics has received a “Decision to grant”, which is an official communication that a patent application has met the requirements for issuance as a granted patent. The Japanese patent still needs to be formally granted.

How long could Oryzon Genomics’ Japanese vafidemstat patent remain in force?

Once formally granted, Oryzon Genomics said the Japanese patent will remain in force until at least 2038, excluding any potential patent term extension. Such an extension could provide additional years of protection.

Which clinical trials is Oryzon Genomics preparing for vafidemstat?

Oryzon Genomics is preparing a Phase III trial of vafidemstat for aggression in borderline personality disorder and a Phase II trial for aggression in autism spectrum disorder patients. A Phase II trial in aggression is already ongoing in schizophrenia.

What is vafidemstat and what is Oryzon Genomics developing it for?

Vafidemstat is Oryzon Genomics’ LSD1 inhibitor in clinical development for the treatment of psychiatric disorders. The company is evaluating it in relation to aggression and other symptoms associated with central nervous system disorders.

What other vafidemstat patent protection does Oryzon Genomics hold?

Oryzon Genomics said it also holds patents covering the use of vafidemstat for central nervous system disorders, including a patent family directed to treating borderline personality disorder or non-aggressive symptoms of borderline personality disorder.

How long are Oryzon Genomics’ other vafidemstat patents expected to remain in force?

Oryzon Genomics said the other patents are expected to remain in force until at least 2040, excluding any potential patent term extensions. Additional applications are pending in other countries.

What did Oryzon Genomics’ Chief IP Officer say about the Japanese patent allowance?

Neus Virgili, Oryzon Genomics’ Chief IP Officer, said the patent allowance in Japan further expands the company’s global patent portfolio and strengthens its intellectual property position for vafidemstat. She said it protects key therapeutic indications under clinical development and supports the drug’s long-term commercial potential.

What type of company is Oryzon Genomics?

Oryzon Genomics describes itself as a clinical-stage biopharmaceutical company focused on epigenetics. Its announcement identifies the company using ISIN Code ES0167733015 and the symbol ORY.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon receives Japanese patent grant decision for vafidemstat application

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon receives Japanese patent grant decision for vafidemstat application

Q: Where has Oryzon Genomics already obtained or allowed corresponding vafidemstat patents?

Oryzon Genomics said corresponding patents have already been granted or allowed in Europe, Australia, Canada, Hong Kong, Israel, South Korea, Malaysia, the Philippines and Russia. Additional applications are pending in other countries.

Published Monday, 02 February 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Regulatory approval
Published: Monday, 02 February 2026
Source announcement: oryzon.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced a Japanese Decision to grant for a vafidemstat patent application.

The Japanese Patent Office sent a Decision to grant communication for application JP2023-136283, titled Methods of treating behavior alterations.
The allowed claims cover vafidemstat, an LSD1 inhibitor in clinical development, for aggression and social withdrawal associated with several CNS disorders.
The communication indicates the application met all requirements for issuance; formal grant is still required.
Once formally granted, the Japanese patent will remain in force until at least 2038, excluding any potential patent term extension.
Oryzon is preparing Phase III and Phase II trials in borderline personality disorder and autism spectrum disorder.

A Phase II trial in schizophrenia is ongoing. Corresponding patents have been granted or allowed in Europe, Australia, Canada, Hong Kong, Israel, South Korea, Malaysia, the Philippines, and Russia; additional applications are pending.

Investor FAQs

Oryzon Genomics announced that it had received a “Decision to grant” communication from the Japanese Patent Office for patent application JP2023-136283, titled “Methods of treating behavior alterations”. The application relates to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for psychiatric disorders.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON strengthens patent portfolio for vafidemstat with new Decision to Grant in Japan
Published: Monday, 02 February 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…